Drug intelligence / Profile preview

daunorubicin + cytarabine + G-CSF-mobilized haploidentical stem cells

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Cell Therapies, Small Molecules
Administration: Intravenous

Overview

This treatment protocol, developed by Memorial Sloan Kettering Cancer Center (MSKCC), is designed for elderly patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The regimen involves standard induction chemotherapy, typically the '7+3' regimen consisting of daunorubicin and cytarabine, followed by the infusion of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (G-PBSC) from a haploidentical related donor. This approach, known as microtransplantation, aims to provide a temporary graft-versus-leukemia (GVL) effect. The donor cells are intended to attack the leukemia briefly before being rejected by the patient's immune system, thereby potentially improving remission rates without the severe toxicities and graft-versus-host disease (GVHD) associated with full allogeneic hematopoietic stem cell transplantation.

Other names: MicrotransplantationInduction chemotherapy followed by G-CSF-mobilized stem cells from haploidentical related donorsMSKCC AML/MDS Microtransplantation Protocolinduction chemotherapy-Memorial Sloan Kettering Cancer Center-acute myeloid leukemia-myelodysplastic syndromes

Beyond the preview

Go deeper on daunorubicin + cytarabine + G-CSF-mobilized haploidentical stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on daunorubicin + cytarabine + G-CSF-mobilized haploidentical stem cells.

Explore the full profile